Please use this identifier to cite or link to this item:
https://dipositint.ub.edu/dspace/handle/2445/204123
Title: | Genotypic and phenotypic study of antiviral resistance mutations in refractory cytomegalovirus infection |
Author: | Santos Bravo, Marta Nicolas Plault Sánchez Palomino, Sonsoles Rodríguez, Cristina Navarro Gabriel, Mireia Mosquera, María Mar Fernández Avilés, Francesc Suarez Lledó, María Rovira, Montserrat Bodro, Marta Moreno Camacho, Ma. Asunción Linares, Laura Cofán Pujol, Federico Berengua, Carla Esteva, Cristina Cordero, Elisa Martín Dávila, Pilar Aranzamendi, Maitane Pérez Jiménez, Ana Belén Vidal, Elisa Fernández Sabé, Núria Len, Óscar Hantz, Sebastien Alain, Sophie Marcos, Ma. Angeles the Spanish Network for Research in Infectious Diseases (REIPI) Group for the Study of Infection in Transplantation (GESITRA) |
Keywords: | Citomegalovirus Resistència als medicaments Cytomegaloviruses Drug resistance |
Issue Date: | 1-Nov-2022 |
Publisher: | Oxford University Press |
Abstract: | Background This study describes the genotypic and phenotypic characterization of novel human cytomegalovirus (HCMV) genetic variants of a cohort of 94 clinically resistant HCMV patients. Methods and results Antiviral-resistant mutations were detected in the UL97, UL54, and UL56 target genes of 25 of 94 (26.6%) patients. The genotype-phenotype correlation study resolved the status of 5 uncharacterized UL54 deoxyribonucleic acid polymerase (G441S, A543V, F460S, R512C, A928T) and 2 UL56 terminase (F345L, P800L) mutations found in clinical isolates. A928T conferred high, triple resistance to ganciclovir, foscarnet, and cidofovir, and A543V had 10-fold reduced susceptibility to cidofovir. Viral growth assays showed G441S, A543V, F345L, and P800L impaired viral growth capacities compared with wild-type AD169 HCMV. Three-dimensional modeling predicted A543V and A928T phenotypes but not R512C, reinforcing the need for individual characterization of mutations by recombinant phenotyping. Conclusions Extending mutation databases is crucial to optimize treatments and to improve the assessment of patients with resistant/refractory HCMV infection. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1093/infdis/jiac349 |
It is part of: | Journal of Infectious Diseases, 2022, vol. 226, num.9, p. 1528-1536 |
URI: | https://hdl.handle.net/2445/204123 |
Related resource: | https://doi.org/10.1093/infdis/jiac349 |
ISSN: | 0022-1899 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
257219.pdf | 2.49 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.